Autres langues Bristol-Myers Squibb Company Lima

Actions

BMY

US1101221083

Temps réel estimé Cboe BZX Autres places de cotation 19:56:59 27/06/2024			Varia. 5j.	Varia. 1 janv.
41,74 ^USD	+1,35 %		+0,64 %	-19,81 %

14:32	Purple Biotech déclare que les données intermédiaires de l'étude sur le cancer du pancréas sont prometteuses	MT
26/06	2seventy bio vend son programme sur l'hémophilie A et sa technologie d'édition de gènes à Novo Nordisk ; les actions montent après les heures de bureau	MT

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	14:32
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	26/06
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	26/06
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06
European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab	24/06
Bristol Myers : approbation accélérée en cancer colorectal	24/06
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)	22/06
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	22/06
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval	21/06
US FDA approves Bristol Myers' colorectal cancer therapy	21/06
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo	21/06
Bristol Myers : demande validée pour Opdivo sous-cutané	21/06
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab	21/06
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo	21/06
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024	20/06
Bristol Myers : l'ex-CEO d'Agilent rejoint le conseil	19/06
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors	18/06
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	18/06

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Christopher Boerner, PDG de Bristol-Myers : Un pipeline de 16 traitements, focus sur les neurosciences et l'oncologie

Le 09 janvier 2024 à 19:06